about Sophiris
Sophiris Bio Inc. (SHS.TO) is a Canadian urology company with operations based in San Diego developing a late-stage, highly targeted treatment for benign prostatic hyperplasia, a large unsatisfied market.
PRX302
Our lead drug candidate for BPH is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions and with none of the sexual side effects that are seen with existing treatments.
investor relations
Sophiris (SHS.TO) is a publicly traded company advised by world-leading urologists, backed by experienced investors, and led by a team that has achieved more than twenty drug approvals including several blockbusters.